Business
Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis
IRVINE, Calif., May 01, 2025--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients.
About this update from Edwards Lifesciences Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/5be9a84e359f4f00b3aa2a795aa36e8b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2ubZp..feICBqRVtnk1oRA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5be9a84e359f4f00b3aa2a795aa36e8b","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/GPNrHuvMKaVCnk9ZpNsSjg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/5be9a84e359f4f00b3aa2a795aa36e8b","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Transforming Care for Severe AS Patients","length":40,"tagName":"p","attribs":{}},{"type":"text","content":"IRVINE, Calif., May 01, 2025--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients.","length":363,"tagName":"p"},{"type":"text","content":"Approval of the SAPIEN 3 platform (SAPIEN 3, SAPIEN 3 Ultra and SAPIEN 3 Ultra RESILIA) is based on groundbreaking data from the EARLY TAVR trial, which demonstrated that asymptomatic severe AS patients randomized to Edwards TAVR experienced superior outcomes compared to guideline-recommended clinical surveillance (watchful waiting).","length":335,"tagName":"p"},{"type":"text","content":"Without treatment, 1 in 10 patients experiencing symptoms of severe AS may die within five weeks. However, the symptoms of severe AS can be difficult to detect and may progress rapidly and unpredictably.","length":203,"tagName":"p"},{"type":"text","content":""There is an urgent need to change practice and TAVR guidelines for the treatment of aortic stenosis patients, which currently recommend ‘watchful waiting’ until symptoms develop," said Philippe Genereux, M.D., director of the structural heart program at Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey. "As we saw in the EARLY TAVR trial, patients originally designated as asymptomatic became sympt...